St. Jude Medical (STJ) : Anchor Capital Advisors reduced its stake in St. Jude Medical by 74.64% during the most recent quarter end. The investment management company now holds a total of 350,221 shares of St. Jude Medical which is valued at $29,253,960 after selling 1,031,035 shares in St. Jude Medical , the firm said in a disclosure report filed with the SEC on Aug 1, 2016.St. Jude Medical makes up approximately 0.75% of Anchor Capital Advisors’s portfolio.
Other Hedge Funds, Including , Courier Capital Corp added STJ to its portfolio by purchasing 2,750 company shares during the most recent quarter which is valued at $229,708. St. Jude Medical makes up approx 0.04% of Courier Capital Corp’s portfolio.Roberts Glore Co Inc Il reduced its stake in STJ by selling 126 shares or 1.34% in the most recent quarter. The Hedge Fund company now holds 9,279 shares of STJ which is valued at $770,528. St. Jude Medical makes up approx 0.57% of Roberts Glore Co Inc Il’s portfolio. Jensen Investment Management Inc sold out all of its stake in STJ during the most recent quarter. The investment firm sold 7,310 shares of STJ which is valued $600,955.Murphy Capital Management Inc reduced its stake in STJ by selling 3,248 shares or 18.27% in the most recent quarter. The Hedge Fund company now holds 14,525 shares of STJ which is valued at $1,180,011. St. Jude Medical makes up approx 0.18% of Murphy Capital Management Inc’s portfolio.Chevy Chase Trust Holdings boosted its stake in STJ in the latest quarter, The investment management firm added 3,222 additional shares and now holds a total of 242,844 shares of St. Jude Medical which is valued at $19,568,370. St. Jude Medical makes up approx 0.11% of Chevy Chase Trust Holdings’s portfolio.
St. Jude Medical closed down -0.08 points or -0.10% at $83.45 with 10,43,777 shares getting traded on Thursday. Post opening the session at $83.31, the shares hit an intraday low of $83.31 and an intraday high of $83.61 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, St. Jude Medical reported $1.06 EPS for the quarter, based on the information available during the earnings call on Jul 20, 2016. Analyst had a consensus estimate of $1.06. The company had revenue of $1562.00 million for the quarter, compared to analysts expectations of $1552.79 million. The company’s revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS.
Many Wall Street Analysts have commented on St. Jude Medical. Company shares were Downgraded by Wedbush on Jul 15, 2016 to ” Neutral”, Firm has raised the Price Target to $ 84 from a previous price target of $70 .St. Jude Medical was Downgraded by Leerink Partners to ” Mkt Perform” on Jul 11, 2016. St. Jude Medical was Downgraded by Sun Trust Rbsn Humphrey to ” Neutral” on May 10, 2016.
St. Jude Medical Inc. develops manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management cardiovascular and atrial fibrillation therapy areas and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. Its six principal product categories include tachycardia implantable cardioverter defibrillator (ICD) systems bradycardia pacemaker systems atrial fibrillation (AF) products (electrophysiology introducers and catheters advanced cardiac mapping navigation and recording systems and ablation systems) vascular products (vascular closure products pressure measurement guidewires optical coherence tomography (OCT) imaging products heart failure monitoring device and other vascular accessories) structural heart products and neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders).